Corsano Health’s Post

💵 Funding News: 🗓️ News Month: October, 2024 🚀 Aignostics Secures $34M to Revolutionize Pathology with AI 🌍 Berlin-based Aignostics is turning complex multimodal pathology data into actionable insights for precision medicine. With a $34M Series B funding round led by Athos Partners and contributions from Mayo Clinic, HTGF | High-Tech Gründerfonds, and other top-tier investors, the company is set to transform healthcare innovation. What’s Next for Aignostics: 🔹New Product Offerings 🎯: Expanding solutions for biopharma clients. 🔹U.S. Expansion 📈: Accelerating growth in the American market. 🔹Collaborative AI Development 🤝: Partnering with Mayo Clinic to build foundation models for pathology. Led by CEO Viktor Matyas, Aignostics leverages proprietary multimodal data, cutting-edge AI technology, and scientific expertise to deliver solutions across: 🔸Drug discovery 💊 🔸Translational research 🔬 🔸Clinical trials 🏥 🔸Companion diagnostics (CDx) 📊 Founded in 2018 as a spin-off from Charité Berlin, Aignostics operates globally with teams in Berlin and New York. 💡 Transforming pathology. Empowering precision medicine. Redefining the future. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

One of the industries that AI will have the greatest impact on, and that effects each of us, is healthcare. These advancements in AI lead to increased automation, standardization, speed in medical evaluations, and ultimately, enhanced precision medicine and improved patient care. AI willl continue to uncover new treatments and preventative measures, leading to increased longevity and improved quality of life. Check out recent discoveries here👇

🚀 Exciting AI Breakthrough in Medicine! 🚀 Insilico Medicine has just achieved a major milestone: Phase IIa success in using AI to treat pulmonary fibrosis! 🌟✨ This revolutionary approach not only promises faster, more cost-effective drug development but also offers hope for better, personalized treatments for a disease that impacts millions worldwide. 🫁 What You Need to Know: Pulmonary fibrosis is a severe condition causing lung tissue scarring and breathing difficulties. Current treatments are limited, but Insilico's AI-driven methods are changing the game! 🔬 Why It Matters: 1. Speed : AI drastically cuts drug development timelines. 2. Cost : Reduces expensive, lengthy trials. 3. Personalization : Tailors treatment to individual patient data. 4. Innovation : Explores a wider range of treatment possibilities. 🎯 This success marks a turning point in medical technology, making treatments quicker, more accessible, and effective. Ready to explore how AI is revolutionizing healthcare? Dive into the full article for all the details and stay tuned for more groundbreaking updates! 🌐🔬👨⚕️ Read more here: [Link to Article]

💵 Funding News: 🗓️ News Month: October, 2024 Ikerian and Retinai Secure $8M in Series B Funding to Revolutionize Eye Care with AI! 👁️✨ Bern-based Ikerian and its Boston subsidiary, RetinAI, are driving the future of healthcare with cutting-edge AI solutions for ophthalmology and beyond. Funding Highlights: 🔸$8M Series B First Close 💰 🔸Led by Sanoptis, with contributions from THINC Ventures (Topcon Healthcare), Zürcher Kantonalbank, and Verve Ventures. What’s Next? 🔹Commercial Rollout 🚀: Expand RetinAI Discovery® and Discovery CONNECT™. 🔹AI Integration 🤖: Enhance patient pre-screening technology for faster clinical trials. 🔹Data Growth 📊: Build a real-world evidence (RWE) database to improve decision-making in care. About RetinAI: Led by Dr. Carlos Ciller, RetinAI develops AI-driven tools for: 🔸Ophthalmology 🏥: Organizing and analyzing health data to help doctors make faster, smarter decisions. 🔸Clinical Workflows 🔬: Partnering with pharmaceutical giants like Novartis, Johnson & Johnson, and Boehringer Ingelheim. By leveraging AI and machine learning, RetinAI is not just accelerating healthcare—it’s redefining it! 🌟 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

Exciting News in the World of Diagnostic Innovation! 🔬 At Connect by Circular-Lab, we are in sync with the advancements in the field and remain committed to advocating for further improvements in the healthcare industry as well as recognizing significant achievements in the diagnostic sector that enhance patient care. We are excited about the collaboration between Quest Diagnostics, a diagnostic information services company, and PathAI Diagnostics, a global leader in artificial intelligence-powered technology for pathology, which have joined forces to accelerate the adoption of digital and AI pathology innovations. At the core of this collaboration lies an agreement for Quest to acquire select assets of PathAI Diagnostics, including its cutting-edge digitized laboratory that will become Quest's AI and digital R&D and solutions center. It is contributing like this to deliver high-quality, efficient, and accessible innovations in oncology which will ultimately pave the way for improved patient care. This strategic collaboration encourages our company, Connect by Circular-Lab, to keep contributing to paving the way for improved patient care thanks to the use of new technologies such as artificial intelligence by collaborating with laboratories, hospitals, professional societies, etc. to deliver more effective diagnoses and treatments.🚀 Join us in this exciting journey towards a future where every patient receives the highest quality care!! #DigitalHealth #PrecisionOncology #ArtificialIntelligenceinHealthcare #HealthcareTransformation

🔬 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: 𝐀𝐈 𝐢𝐧 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐒𝐞𝐭 𝐟𝐨𝐫 𝐑𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐆𝐫𝐨𝐰𝐭𝐡 📈 Download PDF Brochure: https://lnkd.in/g2iCHdhn Exciting market insights reveal that AI in Pathology is poised to revolutionize healthcare diagnostics, projected to reach $169.8M by 2029 from $82.8M in 2024 (CAGR: 15.4%). Key Growth Drivers: • Advanced neural networks (GAN, CNN, RNN) transforming image analysis • Integration of Clinical Decision Support Systems (CDSS) • Streamlined data management and analytics • Accelerated drug discovery processes Industry Impact: ✔️ Hospitals achieving faster, more accurate diagnoses ✔️ Labs enhancing workflow efficiency ✔️ Pharma/Biotech companies speeding up research ✔️ Improved patient outcomes through precise diagnostics 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc., Akoya Biosciences, Inc., Aiforia Technologies, Indica Labs, OptraSCAN, Ibex Medical Analytics, Mindpeak GmbH, Tribun Health, Techcyte, Deep Bio Inc., Lumea, Visiopharm, aetherAI 雲象科技, Aiosyn, Paige AI, Inc. (US), Proscia, PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US) Other Companies that are Operating in this Market Globally: 3DHISTECH - The Digital Pathology Company Advanced Digital Pathology Solutions at PreciPoint StatLab Applied Spectral Imaging (ASI) Morphle Labs Inc. Sakura Finetek USA KUBTEC Medical Imaging Clarapath Surgical Theater Leica Biosystems A.Menarini Diagnostics S.r.l. Tribun Health EndoChoice Fujifilm Healthcare Europe Altimate Medical Sakura Finetek Europe  Inpeco Gen Era Diagnostics Diapath S.p.A Fujifilm Healthcare UK DSS Imagetech Pvt Ltd   Mopec Aperio Profound Medical Inc. Milestone Medical #HealthcareInnovation #AIinHealthcare #DigitalPathology #MedTech #FutureOfHealthcare #HealthTech #ArtificialIntelligence #Healthcare

#HealthcareInnovation >> 🧬 AI Nanobots: Transforming Pharma’s Precision Medicine Landscape 𝗧𝗟𝗧𝗥: AI-powered nanobots are revolutionizing drug delivery and personalized medicine by providing highly targeted and intelligent treatment solutions. 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Nanobots can navigate autonomously within the human body to deliver drugs, genes, or other agents directly to diseased cells. This precision reduces systemic toxicity and side effects, enhancing treatment efficacy and patient safety. 𝗧𝗵𝗲 𝗯𝗶𝗴 𝗽𝗶𝗰𝘁𝘂𝗿𝗲: AI integration enables nanobots to analyze molecular biomarkers, map biological pathways in real time, and determine the most effective treatment plans. This technological advancement promises to revolutionize how we approach drug delivery, microsurgery, and early disease detection. 𝗕𝗲𝘁𝘄𝗲𝗲𝗻 𝘁𝗵𝗲 𝗹𝗶𝗻𝗲𝘀: Beyond immediate medical applications, the development of nanobots could lead to significant healthcare cost reductions and improved patient outcomes. This technology also expands the druggable target space to include previously challenging molecules, addressing a broader range of medical conditions. 𝗧𝗵𝗲 𝗯𝗮𝗰𝗸𝘀𝘁𝗼𝗿𝘆: Traditional drug delivery methods often fail to target diseased sites specifically, leading to high doses and systemic toxicity. The advent of nanobots, especially with AI capabilities, addresses this challenge by offering precision targeting at a molecular level, ensuring that medications are delivered exactly where needed. 𝗪𝗵𝗮𝘁'𝘀 𝗻𝗲𝘅𝘁: The global nanobots market is projected to grow significantly, with advanced applications in diagnostics, surgery, and personalized medicine anticipated within the next decade. Continued research, ethical considerations, and robust regulatory frameworks will be essential to realizing the full potential of this technology in transforming healthcare. Full article: https://lnkd.in/dkKdDmee #Nanobots #PrecisionMedicine #HealthcareInnovation #Pharma #Biotechnology

The AI market in healthcare exploded to $5.7 billion in 2023 and is set to soar beyond $31 billion by 2026, according to MarketsandMarkets. This surge underscores the incredible impact AI is making in transforming healthcare. With nearly 5% of US patients experiencing misdiagnoses, AI is proving to be the essential solution we need! Take PathAI, a trailblazer in AI-powered pathology. Their innovative models are not only enhancing diagnostic accuracy but also playing a crucial role in drug development for complex diseases. Their cutting-edge tool, PathExplore, offers unmatched resolution of tumor microenvironments for various cancer types. Imagine the possibilities: From improving diagnostic precision to accelerating drug discovery, AI is setting new standards in patient care and treatment. At Ditstek Innovations, we're excited to be at the forefront of this transformation. Our team has the capability to develop advanced healthcare applications that integrate AI with Remote Patient Monitoring (RPM) for personalized and efficient care. We design solutions to enhance clinical decision-making, reduce hospitalizations, and ultimately improve health outcomes. Ready to see how AI can revolutionize your healthcare solutions? Let’s work together to shape the future of healthcare! Visit our website: www.ditstek.com, or mail us at info@ditstek.com . . #aiinhealthcare #healthcareinnovation #aiinhealthcare #patientdata #hipaa #healthcarecompliance #healthtech #digitalhealth #healthinnovation #healthcare #drugdevelopment #patientcare #remotepatientmonitoring #healthcaretransformation #futureOfmedicine #airevolution #telemedicine #technology #medical #dits #ditstek #ditstekinnovations #ditstekflorida